Helminth-derived molecules reduced severity across six autoimmune mouse models

Researchers compiled data from hundreds of animal studies testing molecules from roundworms, hookworms, and liver flukes. In asthma models, treated mice showed improved airway function; arthritis animals gained mobility; sepsis mortality dropped sharply; and a University of Galway liver-fluke protein prevented experimental autoimmune encephalomyelitis. These effects occurred via regulatory T-cell expansion and cytokine shifts rather than broad immunosuppression.

The work extends the old-friends hypothesis beyond live-parasite trials that faced regulatory and acceptability barriers. By isolating specific proteins, investigators avoid infection risks while retaining immunomodulatory activity. However, most data remain limited to short-term rodent endpoints; human pharmacokinetics, dosing, and long-term safety are unknown.

Next steps require GMP-grade protein production and phase-1 safety trials. Regulatory precedent for helminth therapies is absent, so FDA and EMA will demand extensive toxicology packages before any autoimmune indication can advance.